ELVN
Enliven Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.70
+3.70%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$38.01
From 52W high−36.71%
Volume1.31M
Market cap$2.84B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$38.01
From 52W high
−36.71%
Volume
1.31M
Market cap
$2.84B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−18.4x
P/E (TTM)
—
RSI (14)
23.8
MomentumView details →
1D Return
+3.70%
YTD Return
+148.43%
SummaryUpdated Jun 1, 2026
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is a clinical-stage biopharmaceutical company founded in 2020 and based in Boulder, Colorado. The company went public on March 12, 2020, and focuses on discovering and developing small molecule inhibitors designed to treat various forms of cancer. As a clinical-stage biotech company, Enliven is currently advancing multiple drug candidates through early-phase clinical trials, with no approved products or revenue to date.
Similar companies
Latest newsMore news →
Enliven Therapeutics appointed Kristine Ball as a Class II director and Audit Committee member, with the appointment effective October 14, 2026.5d agoEnliven Therapeutics, Inc. announced that it reached alignment with the U.S. Food and Drug Administration on the final design of the ENABLE-2 Phase 3 trial of relcobatinib for previously treated chronic myeloid leukemia.13d ago